Dendreon Raises $230 Million To Fund Filing And Anticipated Launch Of Provenge
This article was originally published in The Pink Sheet Daily
Executive Summary
With strong overall survival data in hand for its prostate cancer vaccine, Seattle biotech takes advantage of increased investor interest.
You may also be interested in...
Dendreon Crosses Fingers, Knocks on Wood, And Resubmits Provenge to FDA
The Seattle prostate-cancer vaccine maker has filed again for approval two and a half years after the agency's contentious rejection.
Dendreon Crosses Fingers, Knocks on Wood, And Resubmits Provenge to FDA
The Seattle prostate-cancer vaccine maker has filed again for approval two and a half years after the agency's contentious rejection.
Dendreon Crosses Fingers, Knocks on Wood, And Resubmits Provenge To FDA
Dendreon resubmitted its prostate cancer treatment Provenge (sipuleucel-T) to FDA Nov. 2, two and a half years after the agency disagreed with an advisory panel and rejected the vaccine, which targets metastatic, castration-resistant forms of the disease.